Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China

SARS-CoV-2 Infection, Hospitalization, and Associated Factors Among People Living With HIV in Southeastern China From December 2022 to February 2023: Cross-Sectional Survey

“…According to the Technical Vaccination Recommendations for COVID-19 Vaccines in China and previous studies [16][17][18], vaccination status was categorized into 4 levels: (1) unvaccinated, which indicates no history of COVID-19 vaccination before the last SARS-CoV-2 exposure date; (2) partially vaccinated, which includes people who have received 1 dose of inactivated vaccine, received 2 doses of inactivated vaccine but received the second dose within 14 days before the last SARS-CoV-2 exposure date, received 2 doses of recombinant protein vaccine (3 doses are recommended for full primary vaccination), and received 1 dose of adenovirus vector vaccine, or 3 doses of recombinant protein vaccine but with the last dose within 14 days before the last SARS-CoV-2 exposure date; (3) full primary vaccination, which includes people who received either 2 doses of inactivated vaccine, 1 dose of adenovirus vector vaccine, or 3 doses of recombinant protein (CHO cell) vaccine with the last vaccination 14 days or more before the last SARS-CoV-2 exposure date and with no booster dose; 2 doses of inactivated vaccine with 1 booster dose of inactivated vaccine, adenovirus vector vaccine, or recombinant protein (CHO cell) vaccine within 7 days before the last SARS-CoV-2 exposure date; or 2 doses of adenovirus vector vaccine within 7 days before the last exposure date; (4) booster vaccinated, which includes people who received either 2 doses of Ad5-vector vaccine with the second dose 7 days or more before the last exposure date; or 2 doses of inactivated vaccine and 1 or 2 booster doses of inactivated vaccine, adenovirus vector vaccine, or recombinant protein vaccine 7 days or more before the last exposure date.…”

“…However, there are currently no reports regarding SARS-CoV-2 infection and hospitalization among people living with HIV during this period. Moreover, although a few studies demonstrate the short-duration protection of the COVID-19 vaccine against infection in the general population [ 11 , 12 , 16 , 17 ], there was no study on the impact of the COVID-19 vaccine on infection and hospitalization of SARS-CoV-2 among people living with HIV in China. The substantial epidemic presents an opportunity to evaluate the real-world factors influencing the infection and hospitalization of SARS-CoV-2 among people living with HIV.…”